+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Minimal Residual Disease Testing Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • PDF Icon

    Report

  • 85 Pages
  • July 2025
  • Region: Global
  • Prof Research
  • ID: 6114230
Description Jump to:
Minimal residual disease (MRD) testing represents a sophisticated diagnostic approach designed to detect extremely low levels of cancer cells remaining after initial treatment, utilizing advanced molecular and cellular technologies to identify residual malignant cells below the threshold of conventional diagnostic methods. These cutting-edge systems encompass flow cytometry-based detection, polymerase chain reaction (PCR) amplification techniques, next-generation sequencing (NGS) platforms, and emerging circulating tumor DNA (ctDNA) analysis methods. The technology is extensively applied across hematological malignancies including leukemia and lymphoma, as well as solid tumor applications, primarily utilized in hospitals and specialty clinics, diagnostic laboratories, academic and research institutes, and specialized cancer centers. The market is fundamentally driven by the increasing understanding that MRD status serves as a critical prognostic indicator for treatment response, relapse risk, and long-term survival outcomes. With cancer incidence continuing to rise globally, affecting over 19 million new cases annually, and the growing adoption of precision medicine approaches requiring detailed molecular characterization, MRD testing has become essential for treatment optimization and patient monitoring protocols.

Market Size and Growth Forecast

The global minimal residual disease testing market is projected to reach between USD 2.0 billion and USD 3.0 billion in 2025, with a compound annual growth rate (CAGR) of 8% to 13% through 2030, reflecting the increasing adoption of precision oncology approaches and the growing emphasis on personalized cancer treatment monitoring.

Regional Analysis

  • North America: The United States leads with advanced oncology infrastructure and early adoption of precision medicine technologies, while Canada focuses on expanding access to advanced cancer diagnostics and improving patient outcomes through specialized testing programs.
  • Europe: Germany, France, and the United Kingdom dominate the region, driven by established cancer care networks, comprehensive healthcare systems, and significant investments in oncology research and clinical applications supporting personalized treatment approaches.
  • Asia Pacific: China and India demonstrate rapid growth due to expanding healthcare infrastructure and increasing cancer incidence, while Japan emphasizes advanced molecular diagnostics integration and precision medicine initiatives for improved patient care.
  • Rest of the World: Brazil enhances cancer care capabilities through improved diagnostic infrastructure, while the Middle East, particularly Israel and the UAE, invests in cutting-edge oncology technologies and specialized cancer treatment centers.

Application Analysis

  • Hospitals and Specialty Clinics: Expected growth of 9.0-14.0%, driven by increasing cancer patient volumes and integration of MRD testing into standard care protocols. Trends focus on rapid turnaround times, comprehensive testing panels, and integration with electronic health records for improved treatment decision-making.
  • Diagnostic Laboratories: Projected growth of 8.5-13.5%, linked to centralized testing services and specialized expertise in molecular diagnostics. Developments emphasize high-throughput capabilities, standardized protocols, and advanced bioinformatics platforms for accurate result interpretation.
  • Academic and Research Institutes: Anticipated growth of 7.5-12.0%, driven by clinical research initiatives and biomarker discovery programs. Advances highlight novel detection methods, biomarker validation studies, and translational research applications advancing the field.

Type Analysis

  • Hematological Malignancy: Expected growth of 9.5-14.5%, valued for established clinical utility and well-defined detection methods. Trends focus on standardized protocols, improved sensitivity, and expanded applications across different blood cancer types.
  • Leukemia: Projected growth of 10.0-15.0%, key for treatment monitoring and relapse prediction. Advances highlight multiparameter flow cytometry, molecular markers, and real-time monitoring capabilities improving patient outcomes.
  • Lymphoma: Anticipated growth of 8.5-13.0%, important for prognosis and treatment optimization. Developments prioritize circulating tumor DNA detection, imaging correlation, and personalized monitoring strategies.
  • Solid Tumors: Expected growth of 7.0-12.5%, representing emerging applications with significant potential. Trends emphasize ctDNA analysis, tissue-based assays, and novel biomarker discovery for expanded clinical utility.

Key Market Players

Leading firms include GRAIL, pioneering multi-cancer early detection and MRD monitoring technologies; Veracyte, advancing genomic diagnostics and cancer monitoring solutions; Natera, specializing in genetic testing and circulating tumor DNA analysis; Exact Sciences Corporation, leading colorectal cancer screening and expanding into MRD applications; Foundation Medicine, providing comprehensive genomic profiling and molecular diagnostics; Guardant Health, innovating in liquid biopsy and ctDNA analysis; Roche, offering integrated diagnostic solutions and molecular testing platforms; QIAGEN, providing sample preparation and molecular diagnostic technologies; mdxhealth, focusing on molecular diagnostics for oncology applications; and Bio-Techne, supplying research tools and diagnostic solutions. These companies drive market growth through technological innovations, clinical validation studies, regulatory approvals, and strategic partnerships advancing MRD testing capabilities.

Porter's Five Forces Analysis

  • Threat of New Entrants: Moderate to high, due to significant technological innovation opportunities and venture capital investment, though regulatory requirements, clinical validation needs, and established relationships create barriers for new market participants.
  • Threat of Substitutes: Low to moderate, as MRD testing provides unique clinical value for treatment monitoring, though traditional imaging methods and conventional biomarkers may provide alternative monitoring approaches in specific situations.
  • Bargaining Power of Buyers: Moderate, with healthcare institutions and oncologists seeking clinically validated, cost-effective testing solutions while maintaining high accuracy standards and quick turnaround times for treatment decision-making.
  • Bargaining Power of Suppliers: Low to moderate, due to multiple technology platform options, reagent suppliers, and laboratory service providers, though specialized technologies may create some supplier concentration in specific applications.
  • Competitive Rivalry: High, with companies competing on analytical sensitivity, clinical utility, turnaround time, and cost-effectiveness while building strong relationships with oncology practices and healthcare systems.

Market Opportunities and Challenges

Opportunities: The increasing incidence of hematological malignancies, with over 1.24 million new cases annually worldwide, drives demand for sophisticated monitoring technologies. The growing adoption of CAR-T cell therapy and other advanced immunotherapies requires precise MRD monitoring to assess treatment response and manage potential complications. Technological advances in liquid biopsy platforms, single-cell analysis, and artificial intelligence-enhanced detection methods offer opportunities for improved sensitivity and clinical utility. The expanding applications to solid tumors, including breast, lung, and colorectal cancers, present significant market growth potential as clinical evidence accumulates. Emerging markets demonstrate increasing cancer care infrastructure development and growing awareness of precision medicine benefits.

Challenges: High costs of advanced testing platforms and ongoing reagent expenses limit adoption in resource-constrained healthcare systems and may restrict patient access to optimal monitoring. Complex regulatory pathways for novel diagnostic technologies create lengthy approval processes and increase development costs for manufacturers. The need for extensive clinical validation studies to demonstrate clinical utility and establish appropriate testing algorithms requires significant time and investment. Standardization challenges across different testing platforms and methodologies complicate result interpretation and clinical decision-making. Limited reimbursement coverage for many MRD testing applications restricts market growth and patient access to advanced monitoring technologies. The shortage of specialized laboratory personnel capable of performing and interpreting complex molecular tests constrains market expansion and clinical implementation.

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1 Executive SummaryChapter 2 Abbreviation and Acronyms
Chapter 3 Preface
3.1 Research Scope
3.2 Research Sources
3.2.1 Data Sources
3.2.2 Assumptions
3.3 Research Method
Chapter 4 Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users
Chapter 5 Market Trend Analysis
5.1 Introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats
Chapter 6 Industry Chain Analysis
6.1 Upstream/Suppliers Analysis
6.2 Minimal Residual Disease Testing Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users
Chapter 7 Latest Market Dynamics
7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics
Chapter 8 Historical and Forecast Minimal Residual Disease Testing Market in North America (2020-2030)
8.1 Minimal Residual Disease Testing Market Size
8.2 Minimal Residual Disease Testing Market by End Use
8.3 Competition by Players/Suppliers
8.4 Minimal Residual Disease Testing Market Size by Type
8.5 Key Countries Analysis
8.5.1 United States
8.5.2 Canada
8.5.3 Mexico
Chapter 9 Historical and Forecast Minimal Residual Disease Testing Market in South America (2020-2030)
9.1 Minimal Residual Disease Testing Market Size
9.2 Minimal Residual Disease Testing Market by End Use
9.3 Competition by Players/Suppliers
9.4 Minimal Residual Disease Testing Market Size by Type
9.5 Key Countries Analysis
9.5.1 Brazil
9.5.2 Argentina
9.5.3 Chile
9.5.4 Peru
Chapter 10 Historical and Forecast Minimal Residual Disease Testing Market in Asia & Pacific (2020-2030)
10.1 Minimal Residual Disease Testing Market Size
10.2 Minimal Residual Disease Testing Market by End Use
10.3 Competition by Players/Suppliers
10.4 Minimal Residual Disease Testing Market Size by Type
10.5 Key Countries Analysis
10.5.1 China
10.5.2 India
10.5.3 Japan
10.5.4 South Korea
10.5.5 Southeast Asia
10.5.6 Australia
Chapter 11 Historical and Forecast Minimal Residual Disease Testing Market in Europe (2020-2030)
11.1 Minimal Residual Disease Testing Market Size
11.2 Minimal Residual Disease Testing Market by End Use
11.3 Competition by Players/Suppliers
11.4 Minimal Residual Disease Testing Market Size by Type
11.5 Key Countries Analysis
11.5.1 Germany
11.5.2 France
11.5.3 United Kingdom
11.5.4 Italy
11.5.5 Spain
11.5.6 Belgium
11.5.7 Netherlands
11.5.8 Austria
11.5.9 Poland
11.5.10 Russia
Chapter 12 Historical and Forecast Minimal Residual Disease Testing Market in MEA (2020-2030)
12.1 Minimal Residual Disease Testing Market Size
12.2 Minimal Residual Disease Testing Market by End Use
12.3 Competition by Players/Suppliers
12.4 Minimal Residual Disease Testing Market Size by Type
12.5 Key Countries Analysis
12.5.1 Egypt
12.5.2 Israel
12.5.3 South Africa
12.5.4 Gulf Cooperation Council Countries
12.5.5 Turkey
Chapter 13 Summary For Global Minimal Residual Disease Testing Market (2020-2025)
13.1 Minimal Residual Disease Testing Market Size
13.2 Minimal Residual Disease Testing Market by End Use
13.3 Competition by Players/Suppliers
13.4 Minimal Residual Disease Testing Market Size by Type
Chapter 14 Global Minimal Residual Disease Testing Market Forecast (2025-2030)
14.1 Minimal Residual Disease Testing Market Size Forecast
14.2 Minimal Residual Disease Testing Application Forecast
14.3 Competition by Players/Suppliers
14.4 Minimal Residual Disease Testing Type Forecast
Chapter 15 Analysis of Global Key Vendors
15.1 GRAIL
15.1.1 Company Profile
15.1.2 Main Business and Minimal Residual Disease Testing Information
15.1.3 SWOT Analysis of GRAIL
15.1.4 GRAIL Minimal Residual Disease Testing Revenue, Gross Margin and Market Share (2020-2025)
15.2 Veracyte
15.2.1 Company Profile
15.2.2 Main Business and Minimal Residual Disease Testing Information
15.2.3 SWOT Analysis of Veracyte
15.2.4 Veracyte Minimal Residual Disease Testing Revenue, Gross Margin and Market Share (2020-2025)
15.3 Natera
15.3.1 Company Profile
15.3.2 Main Business and Minimal Residual Disease Testing Information
15.3.3 SWOT Analysis of Natera
15.3.4 Natera Minimal Residual Disease Testing Revenue, Gross Margin and Market Share (2020-2025)
15.4 Exact Sciences Corporation
15.4.1 Company Profile
15.4.2 Main Business and Minimal Residual Disease Testing Information
15.4.3 SWOT Analysis of Exact Sciences Corporation
15.4.4 Exact Sciences Corporation Minimal Residual Disease Testing Revenue, Gross Margin and Market Share (2020-2025)
15.5 FOUNDATION MEDICINE
15.5.1 Company Profile
15.5.2 Main Business and Minimal Residual Disease Testing Information
15.5.3 SWOT Analysis of FOUNDATION MEDICINE
15.5.4 FOUNDATION MEDICINE Minimal Residual Disease Testing Revenue, Gross Margin and Market Share (2020-2025)
15.6 Guardant Health
15.6.1 Company Profile
15.6.2 Main Business and Minimal Residual Disease Testing Information
15.6.3 SWOT Analysis of Guardant Health
15.6.4 Guardant Health Minimal Residual Disease Testing Revenue, Gross Margin and Market Share (2020-2025)
15.7 Roche
15.7.1 Company Profile
15.7.2 Main Business and Minimal Residual Disease Testing Information
15.7.3 SWOT Analysis of Roche
15.7.4 Roche Minimal Residual Disease Testing Revenue, Gross Margin and Market Share (2020-2025)
15.8 QIAGEN
15.8.1 Company Profile
15.8.2 Main Business and Minimal Residual Disease Testing Information
15.8.3 SWOT Analysis of QIAGEN
15.8.4 QIAGEN Minimal Residual Disease Testing Revenue, Gross Margin and Market Share (2020-2025)
15.9 mdxhealth
15.9.1 Company Profile
15.9.2 Main Business and Minimal Residual Disease Testing Information
15.9.3 SWOT Analysis of mdxhealth
15.9.4 mdxhealth Minimal Residual Disease Testing Revenue, Gross Margin and Market Share (2020-2025)
15.10 Bio-Techne
15.10.1 Company Profile
15.10.2 Main Business and Minimal Residual Disease Testing Information
15.10.3 SWOT Analysis of Bio-Techne
15.10.4 Bio-Techne Minimal Residual Disease Testing Revenue, Gross Margin and Market Share (2020-2025)
Tables and Figures
Table Abbreviation and Acronyms
Table Research Scope of Minimal Residual Disease Testing Report
Table Data Sources of Minimal Residual Disease Testing Report
Table Major Assumptions of Minimal Residual Disease Testing Report
Figure Market Size Estimated Method
Figure Major Forecasting Factors
Figure Minimal Residual Disease Testing Picture
Table Minimal Residual Disease Testing Classification
Table Minimal Residual Disease Testing Applications
Table Drivers of Minimal Residual Disease Testing Market
Table Restraints of Minimal Residual Disease Testing Market
Table Opportunities of Minimal Residual Disease Testing Market
Table Threats of Minimal Residual Disease Testing Market
Table COVID-19 Impact For Minimal Residual Disease Testing Market
Table Raw Materials Suppliers
Table Different Production Methods of Minimal Residual Disease Testing
Table Cost Structure Analysis of Minimal Residual Disease Testing
Table Key End Users
Table Latest News of Minimal Residual Disease Testing Market
Table Merger and Acquisition
Table Planned/Future Project of Minimal Residual Disease Testing Market
Table Policy of Minimal Residual Disease Testing Market
Table 2020-2030 North America Minimal Residual Disease Testing Market Size
Figure 2020-2030 North America Minimal Residual Disease Testing Market Size and CAGR
Table 2020-2030 North America Minimal Residual Disease Testing Market Size by Application
Table 2020-2025 North America Minimal Residual Disease Testing Key Players Revenue
Table 2020-2025 North America Minimal Residual Disease Testing Key Players Market Share
Table 2020-2030 North America Minimal Residual Disease Testing Market Size by Type
Table 2020-2030 United States Minimal Residual Disease Testing Market Size
Table 2020-2030 Canada Minimal Residual Disease Testing Market Size
Table 2020-2030 Mexico Minimal Residual Disease Testing Market Size
Table 2020-2030 South America Minimal Residual Disease Testing Market Size
Figure 2020-2030 South America Minimal Residual Disease Testing Market Size and CAGR
Table 2020-2030 South America Minimal Residual Disease Testing Market Size by Application
Table 2020-2025 South America Minimal Residual Disease Testing Key Players Revenue
Table 2020-2025 South America Minimal Residual Disease Testing Key Players Market Share
Table 2020-2030 South America Minimal Residual Disease Testing Market Size by Type
Table 2020-2030 Brazil Minimal Residual Disease Testing Market Size
Table 2020-2030 Argentina Minimal Residual Disease Testing Market Size
Table 2020-2030 Chile Minimal Residual Disease Testing Market Size
Table 2020-2030 Peru Minimal Residual Disease Testing Market Size
Table 2020-2030 Asia & Pacific Minimal Residual Disease Testing Market Size
Figure 2020-2030 Asia & Pacific Minimal Residual Disease Testing Market Size and CAGR
Table 2020-2030 Asia & Pacific Minimal Residual Disease Testing Market Size by Application
Table 2020-2025 Asia & Pacific Minimal Residual Disease Testing Key Players Revenue
Table 2020-2025 Asia & Pacific Minimal Residual Disease Testing Key Players Market Share
Table 2020-2030 Asia & Pacific Minimal Residual Disease Testing Market Size by Type
Table 2020-2030 China Minimal Residual Disease Testing Market Size
Table 2020-2030 India Minimal Residual Disease Testing Market Size
Table 2020-2030 Japan Minimal Residual Disease Testing Market Size
Table 2020-2030 South Korea Minimal Residual Disease Testing Market Size
Table 2020-2030 Southeast Asia Minimal Residual Disease Testing Market Size
Table 2020-2030 Australia Minimal Residual Disease Testing Market Size
Table 2020-2030 Europe Minimal Residual Disease Testing Market Size
Figure 2020-2030 Europe Minimal Residual Disease Testing Market Size and CAGR
Table 2020-2030 Europe Minimal Residual Disease Testing Market Size by Application
Table 2020-2025 Europe Minimal Residual Disease Testing Key Players Revenue
Table 2020-2025 Europe Minimal Residual Disease Testing Key Players Market Share
Table 2020-2030 Europe Minimal Residual Disease Testing Market Size by Type
Table 2020-2030 Germany Minimal Residual Disease Testing Market Size
Table 2020-2030 France Minimal Residual Disease Testing Market Size
Table 2020-2030 United Kingdom Minimal Residual Disease Testing Market Size
Table 2020-2030 Italy Minimal Residual Disease Testing Market Size
Table 2020-2030 Spain Minimal Residual Disease Testing Market Size
Table 2020-2030 Belgium Minimal Residual Disease Testing Market Size
Table 2020-2030 Netherlands Minimal Residual Disease Testing Market Size
Table 2020-2030 Austria Minimal Residual Disease Testing Market Size
Table 2020-2030 Poland Minimal Residual Disease Testing Market Size
Table 2020-2030 Russia Minimal Residual Disease Testing Market Size
Table 2020-2030 MEA Minimal Residual Disease Testing Market Size
Figure 2020-2030 MEA Minimal Residual Disease Testing Market Size and CAGR
Table 2020-2030 MEA Minimal Residual Disease Testing Market Size by Application
Table 2020-2025 MEA Minimal Residual Disease Testing Key Players Revenue
Table 2020-2025 MEA Minimal Residual Disease Testing Key Players Market Share
Table 2020-2030 MEA Minimal Residual Disease Testing Market Size by Type
Table 2020-2030 Egypt Minimal Residual Disease Testing Market Size
Table 2020-2030 Israel Minimal Residual Disease Testing Market Size
Table 2020-2030 South Africa Minimal Residual Disease Testing Market Size
Table 2020-2030 Gulf Cooperation Council Countries Minimal Residual Disease Testing Market Size
Table 2020-2030 Turkey Minimal Residual Disease Testing Market Size
Table 2020-2025 Global Minimal Residual Disease Testing Market Size by Region
Table 2020-2025 Global Minimal Residual Disease Testing Market Size Share by Region
Table 2020-2025 Global Minimal Residual Disease Testing Market Size by Application
Table 2020-2025 Global Minimal Residual Disease Testing Market Share by Application
Table 2020-2025 Global Minimal Residual Disease Testing Key Vendors Revenue
Figure 2020-2025 Global Minimal Residual Disease Testing Market Size and Growth Rate
Table 2020-2025 Global Minimal Residual Disease Testing Key Vendors Market Share
Table 2020-2025 Global Minimal Residual Disease Testing Market Size by Type
Table 2020-2025 Global Minimal Residual Disease Testing Market Share by Type
Table 2025-2030 Global Minimal Residual Disease Testing Market Size by Region
Table 2025-2030 Global Minimal Residual Disease Testing Market Size Share by Region
Table 2025-2030 Global Minimal Residual Disease Testing Market Size by Application
Table 2025-2030 Global Minimal Residual Disease Testing Market Share by Application
Table 2025-2030 Global Minimal Residual Disease Testing Key Vendors Revenue
Figure 2025-2030 Global Minimal Residual Disease Testing Market Size and Growth Rate
Table 2025-2030 Global Minimal Residual Disease Testing Key Vendors Market Share
Table 2025-2030 Global Minimal Residual Disease Testing Market Size by Type
Table 2025-2030 Minimal Residual Disease Testing Global Market Share by Type

Companies Mentioned

  • GRAIL
  • Veracyte
  • Natera
  • Exact Sciences Corporation
  • FOUNDATION MEDICINE
  • Guardant Health
  • Roche
  • QIAGEN
  • mdxhealth
  • Bio-Techne

Related Topics

Related Reports

Minimal Residual Disease Testing Market by Test Type, Application Areas, End-User Vertical - Global Forecast to 2030 - Product Image

Minimal Residual Disease Testing Market by Test Type, Application Areas, End-User Vertical - Global Forecast to 2030

  • Report
  • 185 Pages
  • Global
From
Minimal Residual Disease Testing Market Size, Share & Trends Analysis Report By Technology (NGS, PCR), By Cancer Type (Hematological Malignancy, Solid Tumors), By End-use (Hospitals, Diagnostic Laboratories), By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Minimal Residual Disease Testing Market Size, Share & Trends Analysis Report By Technology (NGS, PCR), By Cancer Type (Hematological Malignancy, Solid Tumors), By End-use (Hospitals, Diagnostic Laboratories), By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 320 Pages
  • Global
From
Minimal Residual Disease Testing: Global Markets and Technologies - Product Image

Minimal Residual Disease Testing: Global Markets and Technologies

  • Report
  • 152 Pages
  • Global
From
Minimal Residual Disease Testing Market Report 2025 - Product Image

Minimal Residual Disease Testing Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Minimal Residual Disease Testing Market Size, Share, Forecast, & Trends Analysis By Offering, Technology, Application Sample - Global Forecast to 2031 - Product Image

Minimal Residual Disease Testing Market Size, Share, Forecast, & Trends Analysis By Offering, Technology, Application Sample - Global Forecast to 2031

  • Report
  • 265 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.